In vivo modulation of the behavioral effects of nicotine by the coumarins xanthotoxin, bergapten, and umbelliferone

Psychopharmacology

Volumn 233, Issue 12, 2016, Pages 2289-2300

  Budzynska, Barbara ^a   Skalicka Wozniak, Krystyna ^a   Kruk Slomka, Marta ^a   Wydrzynska Kuzma, Malgorzata ^a   Biala, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Coumarins; Depression; Memory; Mice; Nicotine

Indexed keywords

BERGAPTEN; METHOXSALEN; NICOTINE; UMBELLIFERONE; 7-HYDROXYCOUMARIN; ANTIDEPRESSANT AGENT; COUMARIN DERIVATIVE; CYTOCHROME P450 2A6; NICOTINIC AGENT; NOOTROPIC AGENT; UMBELLIFERONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; IN VIVO STUDY; INFANT; LEARNING; LOCOMOTION; MALE; MEMORY; MEMORY ACQUISITION; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE TEST; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; AVOIDANCE BEHAVIOR; DRUG EFFECTS; PSYCHOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; COUMARINS; CYTOCHROME P-450 CYP2A6; DEPRESSION; LOCOMOTION; MALE; MEMORY; METHOXSALEN; MICE; NICOTINE; NICOTINIC AGONISTS; NOOTROPIC AGENTS; SWIMMING; UMBELLIFERONES;

EID: 84963721001     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4279-9     Document Type: Article

References (60)

1. Abed MJ, de las Heras B, Silvan AM, Pascual R, Bermejo P, Rodriquez B, Villar AM (2001) Effects of furocoumarins from Cachrys trifida on some macrophage functions. J Pharm Pharmacol 53:163–168
2. Abel T, Lattal KM (2001) Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr Opin Neurobiol 11(2):180–187
3. Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF (2010) Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol 66(3):239–51
4. Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, Dehpour AR (2011) Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 650:240–248
5. Alsharari SD, Siu EC, Tyndale RF, Damaj MI (2014) Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. Nicotine Tob Res 16(1):18–25
6. Bagdas D, Muldoon PP, Zhu AZ, Tyndale RF, Damaj MI (2014) Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 85:67–72
7. Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49:57–71
8. Bethus I, Tse D, Morris RG (2010) Dopamine and memory: modulation of the persistence of memory for novel hippocampal NMDA receptor-dependent paired associates. J Neurosci 30(5):1610–8
9. Biala G, Polak P, Michalak A, Kruk-Slomka M, Budzynska B (2014) Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice. Pharmacol Rep 66(2):212–222
10. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ (1995) The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol 281:319–326
11. Budzynska B, Kruk-Slomka M, Skalicka-Wozniak K, Biala G, Glowniak K (2012a) The effects of imperatorin on anxiety and memory-related behavior in male Swiss mice. Exp Clin Psychopharmacol 20:325–332
12. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, Biala G (2015) Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl) 232(5):931–942
13. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, Biala G, Glowniak K (2013) Effects of imperatorin on nicotine-induced anxiety- and memory-related responses and oxidative stress in mice. Physiol Behav 122:46–55
14. Budzynska B, Polak P, Biala G (2012b) Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm. Behav Brain Res 228(1):144–150
15. Chang TKH, Waxman DJ (1996) The CYP2A5 subfamily. In: Cytochromes. Metabolic and toxicological aspects., pp 430–432
16. Chimakurthy J, Talasila M (2010) Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 3:239–244
17. Cuciureanu M, Vlase L, Muntean D, Varlan I, Cuciureanu R (2010) Grapefruit juice-drug interactions: importance for pharmacotherapy. Rev Med Chir Soc Med Nat Iasi 114(3):885–891
18. Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR (2007) Inhibition of nicotine metabolism by methoxsalen: pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320(1):250–257
19. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446
20. File SE, Cheeta S, Kenny PJ (2000) Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 393:231–236
21. Garcia-Argaez AN, Ramirez Apan TO, Parra Delgado H, Velazquez G, Martinez-Vazquez M (2000) Anti-inflammatory activity of coumarins from Decatropis bicolor on TPA ear mice model. Planta Med 66:279–281
22. Gil-Bea FJ, Solas M, Mateos L, Winblad B, Ramírez MJ, Cedazo-Mínguez A (2011) Cholinergic hypofunction impairs memory acquisition possibly through hippocampal arc and BDNF downregulation. Hippocampus 21(9):999–1009
23. Hayase T (2011) Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. BMC Pharmacol 11:16
24. Herman AI, Sofuoglu M (2010) Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep 12:433–440
25. Hiramatsu M, Murasawa H, Nabeshima T, Kameyama T (1998) Effects of U-50,488H on scopolamine, mecamylamine and dizocilpine-induced learning and memory impairment in rats. J Pharmacol Exp Ther 284:858–867
26. Ho PC, Saville DJ, Wanwimolruk S (2001) Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4(3):217–27
27. Hughes JR (2007) Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9:315–327
28. Hukkanen J, Jacob P III, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharm Rev 57:79–115
29. Huong DTL, Choi HC, Rho TC, Lee HS, Lee MK, Kim YH (1999) Inhibitory activity of monoamine oxidase by coumarins from Peucedanum japonicum. Arch Pharm Res 22(3):324–326
30. Javadi-Paydar M, Zakeri M, Norouzi A, Rastegar H, Mirazi N, Dehpour A (2012) Involvement of nitric oxide in granisetron improving effects on scopolamine-induced memory impairment in mice. Brain Res Rev 1429:61–71
31. Kawaii S, Tomono Y, Ogawa K, Sugiura M, Yano M, Yoshizawa Y, Ito C, Furukawa H (2001) Antiproliferative effects of isopentenylated coumarins on several cancer cell lines. Anticancer Res 21:1905–1911
32. Kielbus M, Skalicka-Wozniak K, Grabarska A, Jeleniewicz W, Dmoszynska-Graniczka M, Marston A, Polberg K, Gawda P, Klatka J, Stepulak A (2013) 7-substituted coumarins inhibit proliferation and migration of laryngeal cancer cells in vitro. Anticancer Res 33:4347–4356
33. Kruk-Slomka M, Budzynska B, Biala G (2012) Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice. Pharmacol Rep 64(5):1066–1080
34. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53:633–640
35. Levin ED, Petro A, Rezvani AH, Pollard N, Christopher NC, Strauss M, Avery J, Nicholson J, Rose JE (2009) Nicotinic α7- or β2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res 196:207–213
36. Levin ED, Rezvani A (2007) Nicotinic interactions with antipsychotic drug models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 74:1182–1191
37. Lucki I (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523–532
38. Luszczki JJ, Anders-Mach M, Glensk M, Skalicka-Wozniak K (2010) Anticonvulsant effects of four linear furanocoumarins, bergapten, imperatorin, oxypeucedanin, and xanthotoxin, in the mouse maximal electroshock-induced seizure model: a comparative study. Pharmacol Rep 62:1231–1236
39. Luszczki JJ, Glowniak K, Czuczwar SJ (2007) Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res 59:18–22
40. Malin DH (2001) Nicotine dependence studies with a laboratory model. Pharmacol Biochem Behav 70:551–559
41. Marubio LM, Arroyo-Jimenez MDM, Cordero-Erausquin M, Léna C, Le Novère N, de Kerchove d’Exaerde A, Huchet M, Damaj MI, Changeux JP (1999) Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398:805–810
42. Murphy SE, Raulinaitis V, Brown KM (2005) Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 33:1166–1173
43. O’Kennedy R, Thornes D (1997) Coumarins: biology, applications and mode of action. Wiley & Sons, Chichester
44. Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, Juvonen RO (2008) Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo. Xenobiotica 38(1):34–47
45. Raunio H, Rahnasto-Rilla M (2012) CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 27(2):73–88
46. Raunio H, Rautio A, Gullstén H, Pelkonen O (2001) Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52(4):357–363
47. Robinson L, Platt B, Riedel G (2011) Involvement of the cholinergic system in conditioning and perceptual memory. Behav Brain Res 221(2):443–65
48. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF (2003) The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicot Tob Res 5(6):891–9
49. Senol FS, Skalicka-Wozniak K, Hassan Khan MT, Orhan IE, Sener B, Glowniak K (2011) An in vitro and in silico approach to cholinesterase inhibitory and antioxidant effects of the methanol extract, furanocoumarin fraction, and major coumarins of Angelica officinalis L. fruits. Phytochem Lett 4:462–467
50. Seon HJ, Xiang HH, Seong SH, Ji SH, Ji HH, Lee D, Myung KL, Jai SR, Bang YH (2006) Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus. Arch Pharm Res 29:1119–1124
51. Singhuber J, Baburin I, Ecker GF, Kopp B, Hering S (2011) Insights into structure–activity relationship of GABAA receptor modulating coumarins and furanocoumarins. Eur J Pharmacol 668:57–64
52. Skalicka-Wozniak K, Mendel M, Chlopecka M, Dziekan N (2015) Isolation and evaluation of the myorelaxant effect of bergapten on isolated rat jejunum. Pharm Biol 17:1–7
53. Skalicka-Wozniak K, Zagaja M, Glowniak K, Luszczki JJ (2014) Purification and anticonvulsant activity of xanthotoxin (8-methoxypsoralen). Centr Eur J Biol 9:431–436
54. Stolerman IP, Shoaib M (1991) The neurobiology of tobacco addiction. Trends Pharmacol Sci 12:467–473
55. Su T, Ding X (2004) Regulation of the cytochrome P450 2A genes. Toxicol Appl Pharmacol 199:285–294
56. Venault P, Chapouthier G, de Carvalho LP, Simiand J, Moore M, Dodd RH, Rossier J (1986) Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 321:864–866
57. Visoni S, Meireles N, Monteiro L, Rossini A, Pinto LFR (2008) Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen. Food Chem Toxicol 46:1190–1195
58. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M (2004) Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. European J Pharm Sci 22:419–425
59. Zaniewska M, Przegalinski E, Filip M (2009) Nicotine dependence—human and animal studies, current pharmacotherapies and future perspectives. Pharmacol Rep 61:957–965
60. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897–902